全国首个医疗机构制剂产业发展专项政策在广州实施

Core Viewpoint - The implementation of the first national policy for the development of the medical institution preparation industry in Guangzhou marks a significant step towards enhancing the quality and efficiency of this sector in China [1][2]. Group 1: Policy Overview - The Guangdong provincial government has introduced specific measures to support the high-quality development of the medical institution preparation industry, which is seen as crucial for the innovation of traditional Chinese medicine and addressing grassroots medication challenges [1]. - The new policy includes 19 specific measures focusing on five key areas: accelerating research and development transformation, restructuring the manufacturing system, expanding resource pools, enhancing service capabilities, and cultivating a financial ecosystem [1][2]. Group 2: Challenges and Solutions - Current challenges in the medical institution preparation industry include low automation in production, insufficient testing accuracy, rising prices of medicinal materials, limited pricing flexibility for preparations, a shortage of professional talent, and difficulties in process inheritance [1]. - The policy aims to address these challenges by proposing a pathway from traditional formulas to innovative drugs, providing policy and financial support across the entire chain from research to clinical trials and production [2]. Group 3: Implementation and Impact - The policy will initially be implemented in Guangzhou, which accounts for a quarter of Guangdong's pharmaceutical manufacturing industry and over 60% of the province's medical institution preparation revenue [2]. - The measures are expected to create a replicable and scalable model for the entire province, promoting collaborative development within the preparation industry [2].